Journals / Balkan Medical Journal / 2021 / Cilt: 38 - Sayı: 6

The Genetic Analysis of Cystic Fibrosis Patients with Seven Novel Mutations in the CFTR Gene in the Central Anatolian Region of Turkey

Pages
357–364
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When no mutations are detected (pathogenic/probably pathogenic) in clinically compatible cases, Multiplex Ligationdependent Probe Amplification analysis contributes significantly to the diagnosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Cystic fibrosis, a pulmonary disease which is an autosomal recessive, inherited, multisystemic genetic disease commonly seen in the Caucasian race, is the most frequent cause of mortality and morbidity.
📊
Key Findings & Data:So far, more than 2000 disease-causing gene variants have been found and this number has been increasing with the studies conducted.
💡
Conclusion & Impact:When no mutations are detected (pathogenic/probably pathogenic) in clinically compatible cases, Multiplex Ligationdependent Probe Amplification analysis contributes significantly to the diagnosis.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: Cystic fibrosis, a pulmonary disease which is an autosomal recessive, inherited, multisystemic genetic disease commonly seen in the Caucasian race, is the most frequent cause of mortality and morbidity. So far, more than 2000 disease-causing gene variants have been found and this number has been increasing with the studies conducted. Although there is not yet enough data that include the Turkish population, the recent increase of studies is noteworthy. Aims: To discover the genetic variation in patients diagnosed with cystic fibrosis in the Central Anatolian region. Study Design: Cross-sectional study. Methods: The study was carried out in the Central Anatolian region in 3 pediatric pulmonology departments (Kayseri, Konya, and Ankara) in Turkey between July 2014 and December 2017. The Sanger and Next Generation Sequence analyses were used for exon and exon–intron boundaries in the cystic fibrosis transmembrane conductance regulatory (CFTR) gene, and in selected patients, mutation analysis was performed using the Multiplex Ligation-dependent Probe Amplification technique for large deletions and duplications. Results: CFTR gene analysis was performed for 316 patients and 215 of them were genetically diagnosed with cystic fibrosis. Sixtythree different variants were defined in these patients and 7 of these were large deletions/duplications detected with the MLPA method. The most frequent variants were F508del (29.6%), G85E (8.2%), N1303K (8.2%), Y515* (7.5%), and G542* (3.4%). Conclusion: Using sequencing and Multiplex Ligation-dependent Probe Amplification methods, the identification of seven new mutations that were not previously reported in the literature contributes to a better understanding of the heterogeneous nature of CFTR mutations in the Turkish population. When no mutations are detected (pathogenic/probably pathogenic) in clinically compatible cases, Multiplex Ligationdependent Probe Amplification analysis contributes significantly to the diagnosis.

🔖

Cite This Article

ASLAN, A. T., BALTA, B., ERDOĞAN, M., KİRAZ, A., PEKCAN, S., KÖSE, M., EYÜPOĞLU, T. Ş., GÜRSOY, T. R., HANGÜL, M., EZGU, F., GÖNEN, G. A., ZAMANİ, A. G., YILDIRIM, M. S. (2022). The Genetic Analysis of Cystic Fibrosis Patients with Seven Novel Mutations in the CFTR Gene in the Central Anatolian Region of Turkey. Balkan Medical Journal, Cilt: 38 - Sayı: 6, 357–364. https://ajindex.com/articles/460797

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Salvatore D, Buzzetti R, Baldo E, et al. An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea. J Cyst Fibros. 2011
  2. 10(2):71-85. [CrossRef] 2. Southern KW, Munck A, Pollitt R, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2007
  3. 6(1):57-65. [CrossRef] 3. Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014
  4. 44(4):1042- 1054. [CrossRef] 4. Hangül M, Pekcan S, Kose M, et al. The incidence of cysticfibrosis in Central Anatolia region of Turkey in 2015 and 2016. Balkan Med J. 2019
  5. Grody WW, Cutting GR, Klinger KW, et al. Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001
  6. 3(2):149-154. [CrossRef] 6. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004
  7. 6(5):387-391. [CrossRef] 7. Schrijver I, Oitmaa E, Metspalu A, Gardner P. Genotyping microarray for the detection of more than 200 CFTR mutations in ethnically diverse populations. J Mol Diagn. 2005
  8. 7(3):375-387. [CrossRef] 8. Shrimpton AE. Molecular diagnosis of cystic fibrosis. Expert Rev Mol Diagn. 2002
  9. 2(3):240-256. [CrossRef] 9. De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016
  10. 4(8):662-674. [CrossRef] 10. Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med. 2016
  11. 4(8):e37-e38. [CrossRef] 11. Kose M, Pekcan S, Kiper N, et al. Doll-like face: is it an under estimated clinical presentation of cystic fibrosis? Pediatr Pulmonol. 2008
  12. 43(7):634-637. [CrossRef] 12. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015
  13. 17(5):405-424. [CrossRef] 13. Onay T, Zielenski J, Topaloglu O, et al. Cystic fibrosis mutations and associated haplotypes in Turkish cystic fibrosis patients. Hum Biol. 2001
  14. 73(2):191-203. [CrossRef] 14. Kilinç MO, Ninis VN, Dağli E, et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF ch